Evidence map›Paper›PMID 25148899›Full record

ArticleMedical oncology (Northwood, London, England)2014

Investigating the association of vascular endothelial growth factor polymorphisms with breast cancer: a Moroccan case-control study.

Jalila Rahoui, Abdelilah Laraqui, Yassir Sbitti, Nadia Touil, Azeddine Ibrahimi, Brahim Ghrab, Abderrahman Al Bouzidi, Driss Moussaoui Rahali, Mohamed Dehayni, Mohamed Ichou and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Predictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomas: a case-control study.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jalila RahouiResearch Team in Molecular Virology and Oncobiology, Faculty of Medicine and Pharmacy, University Mohammed V-Souissi, Mohamed Belarbi El Alaoui, 6203, Rabat, Morocco, rahoui_jalila@yahoo.fr.
Abdelilah Laraqui
Yassir Sbitti
Nadia Touil
Azeddine Ibrahimi
Brahim Ghrab
Abderrahman Al Bouzidi
Driss Moussaoui Rahali
Mohamed Dehayni
Mohamed Ichou
Fatima Zaoui
Saad Mrani
Mohammed V University · MACentre Hospitalier Ibn Sina · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main mediator of breast cancer (BC) angiogenesis is the vascular endothelial growth factor (VEGF). Variation of VEGF-A gene may influence the BC susceptibility. The present case-control study investigated the association of the four commonly studied single nucleotide polymorphisms (SNP) of VEGF-A, namely: -1154A/G (rs1570360), -2578C/A (rs699947), -634G/C (rs2010963) and -460T/C (rs833061) with BC susceptibility and aggressiveness in Moroccan women. After genomic DNA extraction, genotyping was performed by TaqMan SNP assays on 70 BC patients and 70 healthy women. The χ2 test was used to detect differences in the genotype frequencies of VEGF between the groups and to stratify genotypes by the clinico-pathological characteristics in patient's group. Women carriers of -1154AG + AA and -2578AC + AA VEGF genotypes had a reduced risk to develop BC [p = 0.018, OR 2.25 95 % CI (1.14-4.42) and p = 0.022, OR 2.26 95 % CI (1.12-4.58), respectively]. Carriers of -460CT and CT + CC genotypes had also a reduced risk to develop BC [p = 0.045, OR 2.63 95 % CI (1.19-5.84) and p = 0.043, OR 2.12 95 % CI (1.01-4.43), respectively]. Moreover, the A-1154A-2578G-634C-460 haplotype seems to have a protective effect against BC risk [p = 0.007, OR 2.41 95 % CI (1.27-4.55)]. Stratification for BC patients according to clinico-pathological characteristics reveals no association with any of VEGF-A SNPs. In conclusion, the data indicated significant associations of VEGF -1154A/G, -2578C/A and -460T/C polymorphisms with BC susceptibility in Moroccan individuals. These VEGF-A polymorphisms can be useful as predisposing genetic markers for BC. Further larger-scale studies are necessary to confirm our finding.

Indexed as

AdultAgedBreast NeoplasmsCase-Control StudiesFemaleGene FrequencyHaplotypesHumansMiddle AgedMoroccoPolymorphism, Single NucleotideVascular Endothelial Growth Factor AYoung AdultVascular Endothelial Growth Factor A

Identifiers

PMID25148899
OpenAlexW2025841195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.